Notícias

Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension as the Discounted Cash Flow (DCF) intrinsic value suggests the shares trade at a discount while the broader scorecard still leans expensive. A roughly 5x gain over five years can signal that a lot of optimism is already reflected in Eli Lilly’s share price, putting more focus on what investors are paying for that growth story today. Expectations tied to obesity,...

Viking's latest program seeks to push the envelope in weight loss efficacy.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the

Novo Nordisk is finally getting one up on its biggest rival.

Omada, an Eli Lilly partner, has soared more than 118% in just a few months, moving up the right side of a new base.

Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.

Find insight on Eli Lilly, GSK, Intuitive Surgical and more in the latest Market Talks covering the Health Care sector.

Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.

Big pharma is making a big bet that a DMT nasal spray could succeed where daily Prozac pills fall short.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...

Companies In The Article Are:ASTS,ATAI,LLY,USB,CFG

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.

Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and contingent value rights deal valued at up to $3.8b, putting fresh focus on the stock’s risk and return trade off. See our latest analysis for AtaiBeckley. AtaiBeckley’s share price has reacted sharply to the Eli Lilly bid, with a 33.4% 1 day share price return on the announcement and an 84.75% year to date share price return. The 1 year total shareholder return of 156.27% contrasts with a 5 year total...

Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic...

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

The deal gives Eli Lilly access to a ⁠psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.

Apple, AtaiBeckley and UnitedHealth Group jumped to yearly highs as positive company catalysts, Wall Street upgrades, and strong earnings pushed shares higher.

AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly agreed to acquire the company for up to $3.8 billion. In intra-day trading, the stock surged to a record high of $7.22 before trimming gains to end the session just up by 33.40 percent at […]

The psychedelic drugmaker is being acquired.

Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July. Guggenheim, Truist, Bank of America, Bernstein, and JPMorgan all raised their price targets in the first half of the month. Then UBSwent higher than nearly all of them. UBS's call is worth watching closely because ...

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

Acquisition could strengthen its neuroscience growth strategy

The deal gives Lilly a late-stage psychedelic treatment for hard-to-treat depression.

Lilly will pay $6.75 a share in cash, plus up to $1 billion in milestones

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.